Results 121 to 130 of about 2,365,735 (268)

Time- and Temperature-Dependent Response of Acquired FV Inhibitors: Implications for Laboratory Diagnosis and Clinical Management. [PDF]

J Clin Lab Anal
Zhang L, Li M, Xie Z, Yao J, Cao Y, Chen L, Wang M.   +6 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

A collaborative approach to improve neurotrauma care and data collection – the GEO-TBI registry

Brain and Spine
Dr. Tommi Kalevi Korhonen, Mr Midhun Mohan, Mr David Clark, Ms Sara Venturini, Mr Michael Martin, Mr Angelos Kolias, Mr Alexis Joannides, Peter Hutchinson   +7 more
doaj   +1 more source

3D Simultaneous Post-contrast T1/T2 Mapping and Synthetic Multi-Contrast Late Gadolinium Enhancement at 0.55T: Validation in Porcine Myocardial Infarction Model. [PDF]

Invest Radiol
Si D, Varghese J, Littlewood SJ, Binzel K, Pervaiz S, Mergaye M, Khan M, Han Y, Kunze KP, Crabb MG, Simonetti OP, Prieto C, Botnar RM.   +12 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Facial palsy reveals the sensorimotor contribution to facial-emotion recognition. [PDF]

Proc Natl Acad Sci U S A
Sessa P, Schiano Lomoriello A, Quettier T, Maffei A, Costa S, Nichele M, Ferrari PF.   +6 more
europepmc   +1 more source

Acquired cholesteatoma

Canadian Medical Association Journal
Newsted, Daniel, Bajin, Munir Demir, You, Peng   +2 more
openaire   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Acquired carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 1997
openaire   +2 more sources

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source